Analyze Diet

Topic:Vaccine development

Vaccine development in horses involves the creation and refinement of immunizations to protect equine populations from infectious diseases. This process includes identifying antigens, formulating vaccines, and evaluating their safety and efficacy through clinical trials. Vaccines stimulate the horse's immune system to recognize and combat specific pathogens, thereby reducing the incidence and severity of diseases. Common equine vaccines target diseases such as equine influenza, tetanus, and West Nile virus. This page compiles peer-reviewed research studies and scholarly articles that explore the methodologies, challenges, and advancements in vaccine development for equine health.
Equine influenza vaccine efficacy: the significance of antigenic variation.
Veterinary microbiology    May 9, 2000   Volume 74, Issue 1-2 173-177 doi: 10.1016/s0378-1135(00)00177-2
Yates P, Mumford JA.To investigate the level of cross-protection induced by equine influenza H3N8 vaccines derived from different lineages, two studies have been carried out with ponies vaccinated with 'American-like' and 'European-like' vaccines and experimentally challenged with a European-like strain. The results demonstrated that equine influenza vaccines clearly protect against challenge with homologous virus if serum antibody titres are sufficiently high. On the other hand, protection is incomplete even when animals vaccinated with heterologous strains have comparative antibody levels. Nevertheless, the pro...
DNA vaccination against influenza viruses: a review with emphasis on equine and swine influenza.
Veterinary microbiology    May 9, 2000   Volume 74, Issue 1-2 149-164 doi: 10.1016/s0378-1135(00)00175-9
Olsen CW.The influenza virus vaccines that are commercially-available for humans, horses and pigs in the United States are inactivated, whole-virus or subunit vaccines. While these vaccines may decrease the incidence and severity of clinical disease, they do not consistently provide complete protection from virus infection. DNA vaccines are a novel alternative to conventional vaccination strategies, and offer many of the potential benefits of live virus vaccines without their risks. In particular, because immunogens are synthesized de novo within DNA transfected cells, antigen can be presented by MHC c...
Equine immunity to parasites.
The Veterinary clinics of North America. Equine practice    April 7, 2000   Volume 16, Issue 1 69-vi doi: 10.1016/s0749-0739(17)30119-0
Klei TR.Helminths are among the most significant parasites of horses in developed countries. This article examines immune responses against helminth parasites and the implications that immunologic investigations have on vaccine development, improvement of diagnostic procedures, and disease eradication.
Equine T-cell cytokines. Protection and pathology.
The Veterinary clinics of North America. Equine practice    April 7, 2000   Volume 16, Issue 1 1-14 doi: 10.1016/s0749-0739(17)30115-3
Horohov DW.The ultimate reason for better characterizing the immune response to infectious agents is the hope that this knowledge may lead to the development of better preventative or therapeutic measures. As more information becomes available, it becomes possible to incorporate these findings into the design of better vaccines and treatments. Likewise, attempts to either enhance or suppress specific helper T-cell responses may be required to control immunopathologic reactions. Although cytokine intervention in the clinical setting remains theoretic at this time, future manipulation based on the TH1/TH2 ...
Equine immunity to viruses.
The Veterinary clinics of North America. Equine practice    April 7, 2000   Volume 16, Issue 1 49-68 
Slater J, Hannant D.The identification of some of the adaptive immune responses to infection with equine viruses has been the first step toward rational immunoprophylactic design. Sufficient knowledge of infection-induced immunity and informed estimates of the requirements for long-term immunity for EIV have now been obtained. Thus, the future for inactivated EIV vaccines is promising now that new adjuvants have been applied to induce cellular immunity and safe methods have been designed to stimulate virus-neutralizing (VN) antibody at mucosal surfaces. Adenoviruses induce circulating VN antibody, the presence of...
Immune responses in mice, cattle and horses to a DNA vaccine for vesicular stomatitis.
Vaccine    March 30, 2000   Volume 18, Issue 22 2368-2374 doi: 10.1016/s0264-410x(00)00007-4
Cantlon JD, Gordy PW, Bowen RA.Vesicular stomatitis (VS) virus causes an important clinical disease of cattle and horses in North America. In order for a vaccine to be useful in the control of VS, it must not only protect against disease, but allow ready differentiation of infected and vaccinated animals. In these studies, we evaluated neutralizing antibody responses in outbred mice, calves, and horses that received a DNA vaccine that expressed the glycoprotein (G) gene of VS New Jersey virus. The vaccine elicited antibody titers in individuals from each species, especially when two doses were administered, but the level of...
Possible mechanisms of mammalian immunocontraception.
Journal of reproductive immunology    March 9, 2000   Volume 46, Issue 2 103-124 doi: 10.1016/s0165-0378(99)00063-7
Barber MR, Fayrer-Hosken RA.Ecological and conservation programs in ecosystems around the world have experienced varied success in population management. One of the greatest problems is that human expansion has led to the shrinking of wildlife habitat and, as a result, the overpopulation of many different species has occurred. The pressures exerted by the increased number of animals has caused environmental damage. The humane and practical control of these populations has solicited the scientific community to arrive at a safe, effective, and cost-efficient means of population control. Immunocontraception using zona pellu...
Veterinary vaccinology.
Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie    January 26, 2000   Volume 322, Issue 11 967-972 doi: 10.1016/s0764-4469(00)87194-2
Pastoret PP.Veterinary vaccinology is a very interesting and rapidly developing field. In fact veterinary vaccines are not only used for the prevention of infectious diseases in the animal health sector, but also help to solve problems of public health, to reduce detrimental environmental impact of the use of some veterinary drugs and prevent the emergence of resistance of micro-organisms or parasites. After a short introduction, this paper will deal with the use of vaccines for animal health and welfare, including new developments in the veterinary field such as marker vaccines and vectored vaccines, the...
Complete genomic RNA sequence of western equine encephalitis virus and expression of the structural genes.
The Journal of general virology    January 21, 2000   Volume 81, Issue Pt 1 151-159 doi: 10.1099/0022-1317-81-1-151
Netolitzky DJ, Schmaltz FL, Parker MD, Rayner GA, Fisher GR, Trent DW, Bader DE, Nagata LP.The complete nucleotide sequence of the 71V-1658 strain of western equine encephalitis virus (WEE) was determined (minus 25 nucleotides from the 5' end). A 5' RACE reaction was used to sequence the 5' terminus from WEE strain CBA87. The deduced WEE genome was 11508 nucleotides in length, excluding the 5' cap nucleotide and 3' poly(A) tail. The nucleotide composition was 28% A, 25% C, 25% G and 22% U. Comparison with partial WEE sequences of strain 5614 (nsP2-nsP3 of the nonstructural region) and strain BFS1703 (26S structural region) revealed comparatively little variation; a total of 149 nucl...
Equine sarcoid tumour treated by autogenous tumour vaccine.
Anticancer research    January 12, 2000   Volume 19, Issue 4C 3367-3374 
Kinnunen RE, Tallberg T, Stenbäck H, Sarna S.Twenty-one horses with sarcoid tumours were treated by bio-immunotherapy using autogenous vaccines during 1991-1997. At operation the base of the tumour was left in the skin and autovaccines were made from extirpated tumour tissue by polymerization. The horses thus formed their own internal control group. One of 12 horses having a primary tumour, and four of 9 horses suffering recurrent tumours, prior to bio-immunotherapy, developed single recurrences. Four of these five horses suffering recurrence were treated anew, leading to remission. Disease-free intervals were longer for primary (P = 0.0...
‘Cross-protection’ and ‘cross-reaction’ with equine influenza vaccines.
The Veterinary record    January 5, 2000   Volume 145, Issue 22 647 
Newton JR, Wood JL, Jessett D, Yates PJ, Mumford JA.No abstract available
Immune responses in a horse inoculated with the VP2 gene of African horsesickness virus.
The Onderstepoort journal of veterinary research    November 24, 1999   Volume 66, Issue 2 139-144 
Romito M, Du Plessis DH, Viljoen GJ.The ability of a DNA vaccine to elicit an immune response in a horse was evaluated. The outer capsid protein VP2 of African horsesickness virus is known to elicit protective immunity in horses. Reverse transcribed DNA of the gene encoding VP2 was placed under the transcriptional control of the cytomegalovirus immediate-early enhancer/promoter and was injected on several occasions intramuscularly into a horse. Low antibody levels could be detected by ELISA. Antibodies directed against VP2 alone were shown by Western blot while low levels of neutralizing antibodies were detected by a 50% plaque ...
Vaccination against lyme disease with recombinant Borrelia burgdorferi outer-surface protein A (rOspA) in horses.
Vaccine    October 16, 1999   Volume 18, Issue 5-6 540-548 doi: 10.1016/s0264-410x(99)00187-5
Chang Y, Novosol V, McDonough SP, Chang CF, Jacobson RH, Divers T, Quimby FW, Shin S, Lein DH.Eight 1-year-old ponies were vaccinated with recombinant OspA (ospA gene derived from B. burgdorferi B31) with adjuvant (aluminium hydroxide). Four ponies were used as non-vaccinated controls with adjuvant. One hundred and twelve days after the first vaccination, the vaccinated and non-vaccinated ponies were challenged by exposure to B. burgdorferi-infected adults tick (Ixodes scapularis) collected from Westchester County, New York (tick infection rate >/=60%). Protection from infection was evaluated by culture for B. burgdorferi from three monthly skin biopsies taken near the site of tick bit...
Determination of equid herpesvirus 1-specific, CD8+, cytotoxic T lymphocyte precursor frequencies in ponies.
Veterinary immunology and immunopathology    October 3, 1999   Volume 70, Issue 1-2 43-54 doi: 10.1016/s0165-2427(99)00037-9
O'Neill T, Kydd JH, Allen GP, Wattrang E, Mumford JA, Hannant D.The frequency of antigen-specific, genetically restricted cytotoxic T lymphocyte precursors (CTLp) was measured in peripheral blood mononuclear cells (PBMC) of ponies before and after infection with equid herpesvirus 1 (EHV1). Split-well limiting dilution analysis (LDA) was developed to measure CTLp frequency using EHV1-infected 51Cr-labelled lymphoblasts as targets. Extensive characterisation showed that recombinant human interleukin-2, autologous antigen presenting cells and equine serum containing virus neutralising antibody were necessary for maturation of CTLp into effector CTL in vitro. ...
[Mutations in the US2 and glycoprotein B genes of the equine herpesvirus 1 vaccine strain RacH have no effects on its attenuation].
Berliner und Munchener tierarztliche Wochenschrift    October 3, 1999   Volume 112, Issue 9 351-354 
Neubauer A, Meindl A, Osterrieder N.The equine herpesvirus 1 (EHV-1) modified live vaccine strain RacH is apathogenic for both laboratory animals and the natural host. The apathogenicity of RacH was caused by serial passages of the virus in heterologous cells. When compared to the virulent parental strain RacL11 several changes in the RacH genome occurred. Previous results have shown that the loss of the IR6 gene correlated with the loss of virulence. Additional important mutations were observed within the US2 gene which is directly adjacent to the IR6 gene and within the glycoprotein B (gB) gene. To answer the question whether ...
Evaluation of antibody parameters as potential correlates of protection or enhancement by experimental vaccines to equine infectious anemia virus.
Virology    September 30, 1999   Volume 262, Issue 2 416-430 doi: 10.1006/viro.1999.9939
Hammond SA, Raabe ML, Issel CJ, Montelaro RC.We previously demonstrated in trials of a variety of experimental vaccines to equine infectious anemia virus (EIAV) a remarkable spectrum of efficacy ranging from sterilizing protection to severe enhancement of virus replication and disease, depending on the immunization strategy used. This range of vaccine efficacy observed in vivo offers a unique opportunity for evaluating potential in vitro immune correlates of protection and enhancement. We describe here a comprehensive analysis and comparison of EIAV envelope-specific antibody responses elicited by attenuated, inactivated whole virus and ...
Comparison of the pathogenesis of acute equine herpesvirus 1 (EHV-1) infection in the horse and the mouse model: a review.
Veterinary microbiology    September 29, 1999   Volume 68, Issue 1-2 3-13 doi: 10.1016/s0378-1135(99)00056-5
Walker C, Love DN, Whalley JM.The mouse models of the respiratory and abortion forms of equine herpesvirus 1 (EHV-1) infection have been used to investigate the vaccine potential of various EHV-1 immunogens, the effect of antiviral agents on EHV-1 infection and the pathogenicity of EHV-1 strain variants and deletion or insertional mutants. This review examines the similarities and differences in the pathogenesis of primary EHV-1 infection in the natural host, the horse, and in the mouse by comparing tissue tropism, clinical signs of infection, the effects of EHV-1 on pregnancy, haematological changes following infection, v...
Potential of DNA-mediated vaccination for equine herpesvirus 1.
Veterinary microbiology    September 29, 1999   Volume 68, Issue 1-2 35-48 doi: 10.1016/s0378-1135(99)00059-0
Ruitenberg KM, Walker C, Wellington JE, Love DN, Whalley JM.The potential of DNA-mediated immunisation to protect against equine herpesvirus 1 (EHV-1) disease was assessed in a murine model of EHV-1 respiratory infection. Intramuscular injection with DNA encoding the EHV-1 envelope glycoprotein D (gD) in a mammalian expression vector induced a specific antibody response detectable by two weeks and maintained through 23 weeks post injection. Immune responses were proportional to the dose of DNA and a second injection markedly enhanced the antibody response. EHV-1 gD DNA-injected mice developed neutralising antibodies, and a predominance of IgG2a antibod...
Questions validity of equine vaccine field studies.
Journal of the American Veterinary Medical Association    September 7, 1999   Volume 215, Issue 5 620-621 
Piontkowski MD.No abstract available
Genetic evidence for the origins of Venezuelan equine encephalitis virus subtype IAB outbreaks.
The American journal of tropical medicine and hygiene    August 31, 1999   Volume 60, Issue 3 441-448 doi: 10.4269/ajtmh.1999.60.441
Weaver SC, Pfeffer M, Marriott K, Kang W, Kinney RM.Epizootics of Venezuelan equine encephalitis (VEE) involving subtype IAB viruses occurred sporadically in South, Central and North America from 1938 to 1973. Incompletely inactivated vaccines have long been suspected as a source of the later epizootics. We tested this hypothesis by sequencing the PE2 glycoprotein precursor (1,677 nucleotides) or 26S/nonstructural protein 4 (nsP4) genome regions (4,490 nucleotides) for isolates representing most major outbreaks. Two distinct IAB genotypes were identified: 1) 1940s Peruvian strains and 2) 1938-1973 isolates from South, Central, and North America...
Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene.
Vaccine    July 14, 1999   Volume 17, Issue 18 2245-2258 doi: 10.1016/s0264-410x(98)00496-4
Lunn DP, Soboll G, Schram BR, Quass J, McGregor MW, Drape RJ, Macklin MD, McCabe DE, Swain WF, Olsen CW.Equine influenza virus infection remains one of the most important infectious diseases of the horse, yet current vaccines offer only limited protection. The equine immune response to natural influenza virus infection results in long-term protective immunity, and is characterized by mucosal IgA and serum IgGa and IgGb antibody responses. DNA vaccination offers a radical alternative to conventional vaccines, with the potential to generate the same protective immune responses seen following viral infection. Antigen-specific antibody isotype responses in serum and mucosal secretions were studied i...
Antigenic profile of African horse sickness virus serotype 4 VP5 and identification of a neutralizing epitope shared with bluetongue virus and epizootic hemorrhagic disease virus.
Virology    May 18, 1999   Volume 257, Issue 2 449-459 doi: 10.1006/viro.1999.9680
Martínez-Torrecuadrada JL, Langeveld JP, Venteo A, Sanz A, Dalsgaard K, Hamilton WD, Meloen RH, Casal JI.African horse sickness virus (AHSV) causes a fatal disease in horses. The virus capsid is composed of a double protein layer, the outermost of which is formed by two proteins: VP2 and VP5. VP2 is known to determine the serotype of the virus and to contain the neutralizing epitopes. The biological function of VP5, the other component of the capsid, is unknown. In this report, AHSV VP5, expressed in insect cells alone or together with VP2, was able to induce AHSV-specific neutralizing antibodies. Moreover, two VP5-specific monoclonal antibodies (MAbs) that were able to neutralize the virus in a ...
Gag protein epitopes recognized by CD4(+) T-helper lymphocytes from equine infectious anemia virus-infected carrier horses.
Journal of virology    April 10, 1999   Volume 73, Issue 5 4257-4265 doi: 10.1128/JVI.73.5.4257-4265.1999
Lonning SM, Zhang W, McGuire TC.Antigen-specific T-helper (Th) lymphocytes are critical for the development of antiviral humoral responses and the expansion of cytotoxic T lymphocytes (CTL). Identification of relevant Th lymphocyte epitopes remains an important step in the development of an efficacious subunit peptide vaccine against equine infectious anemia virus (EIAV), a naturally occurring lentivirus of horses. This study describes Th lymphocyte reactivity in EIAV carrier horses to two proteins, p26 and p15, encoded by the relatively conserved EIAV gag gene. Using partially overlapping peptides, multideterminant and poss...
Detection and induction of equine infectious anemia virus-specific cytotoxic T-lymphocyte responses by use of recombinant retroviral vectors.
Journal of virology    March 12, 1999   Volume 73, Issue 4 2762-2769 doi: 10.1128/JVI.73.4.2762-2769.1999
Lonning SM, Zhang W, Leib SR, McGuire TC.Cytotoxic T lymphocytes (CTL) appear to be critical in resolving or reducing the severity of lentivirus infections. Retroviral vectors expressing the Gag/Pr or SU protein of the lentivirus equine infectious anemia virus (EIAV) were constructed and used to evaluate EIAV-specific CTL responses in horses. Three promoters, cytomegalovirus, simian virus SV40, and Moloney murine sarcoma virus (MoMSV) long terminal repeat (LTR), were used, and there was considerable variation in their ability to direct expression of Gag/Pr and SU. Vectors expressing EIAV proteins under the direction of MoMSV LTR and ...
Diagnosis and prevention of equine infectious diseases: present status, potential, and challenges for the future.
Advances in veterinary medicine    January 16, 1999   Volume 41 359-377 doi: 10.1016/s0065-3519(99)80027-5
Desmettre P.The frequent transfers of horses, whether on a permanent or temporary basis, make strict control of infectious diseases essential. Such control needs a reliable and rapid means to accurately diagnose the relevant diseases. Indirect diagnosis based on antibody detection remains certainly the best method to secure the epidemiologic surveillance of the diseases at regional, national, or even world level, while direct diagnosis is the only way to diagnose a new outbreak. New diagnostic methods resulting from advances in biochemistry, molecular biology, and immunology are now available. As far as a...
Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia. MAS054 Clinical Investigator Group.
Bulletin of the World Health Organization    December 30, 1998   Volume 76, Issue 5 491-495 
Lang J, Simanjuntak GH, Soerjosembodo S, Koesharyono C.WHO's reference protocol for post-exposure rabies vaccination advises five intramuscular injections on days 0, 3, 7, 14, and 30; in addition, rabies immunoglobulins (RIG) must be given to serious cases of exposure (grade III severity). Some studies indicate that these immunoglobulins suppress the immunogenicity of rabies vaccine when administered according to an alternative protocol of four injections (2-1-1) on days 0, 7, and 21, which was therefore not recommended for grade III exposures. To test this effect, we conducted a multicentre study in Indonesia using three groups of subjects. One g...
Future international management of African horse sickness vaccines.
Archives of virology. Supplementum    October 24, 1998   Volume 14 297-304 doi: 10.1007/978-3-7091-6823-3_25
House JA.Three types of African horse sickness (AHS) vaccine, namely adult mouse brain, modified live vaccine and inactivated viral vaccine (IVV) are reviewed. The results of efficacy trials carried out with each vaccine type highlight the advantages of the IVV. Vaccination with African horse sickness virus serotype 4 IVV, given as 2 separate doses, provided full protection against subsequent, homologous challenge. The absence of any detectable viraemia after challenge would also prevent infection of insect vectors. The advantages of establishing international vaccine banks for AHS are discussed.
Western immunoblotting as a method for the detection of African horse sickness virus protein-specific antibodies: differentiation between infected and vaccinated horses.
Archives of virology. Supplementum    October 24, 1998   Volume 14 329-336 doi: 10.1007/978-3-7091-6823-3_29
Bougrine SI, Fihri OF, Fehri MM.A Western immunoblotting procedure has been developed for the detection of African horse sickness virus (AHSV) protein-specific antibody responses. This assay readily identifies antibodies specific for at least 4 distinct, AHSV proteins, including VP5, NS1, NS2 and NS3/NS3a. By using the AHSV non-structural proteins as 'markers', the Western blotting procedure could be employed to provide a reliable means of discriminating between animals vaccinated with a purified, inactivated AHSV vaccine and those either naturally infected or vaccinated with a live, attenuated AHSV vaccine.
Local and systemic isotype-specific antibody responses to equine influenza virus infection versus conventional vaccination.
Vaccine    July 31, 1998   Volume 16, Issue 13 1306-1313 doi: 10.1016/s0264-410x(98)00009-7
Nelson KM, Schram BR, McGregor MW, Sheoran AS, Olsen CW, Lunn DP.Inactivated alum-adjuvanted conventional equine influenza virus vaccines are of poor efficacy and offer limited short-term protection against infection. In sharp contrast, natural infection with equine influenza virus confers long-term protective immunity. In order to identify the protective immune responses to equine influenza virus, the influenza virus-specific IgA, IgGa, IgGb, IgGc and IgG(T) antibody responses in nasal secretions and serum induced by natural infection and a commercial vaccine were studied by ELISA. Two groups of four influenza-naive ponies were established. In the natural ...
Molecular basis for antigenic variation of a protective strain-specific antigen of Ehrlichia risticii.
Infection and immunity    July 23, 1998   Volume 66, Issue 8 3682-3688 doi: 10.1128/IAI.66.8.3682-3688.1998
Biswas B, Vemulapalli R, Dutta SK.Ehrlichia risticii, the causative agent of Potomac horse fever, has recently been isolated from many vaccinated horses with typical clinical signs of the disease. The heterogeneity of the E. risticii isolates obtained from the vaccinated horses necessitates the identification of the molecular basis of strain variations to elucidate the vaccine failure and to aid in the development of an efficient vaccine against this disease. As an attempt, two major cross-reacting surface antigen genes of 50- and 85-kDa antigens, present separately in strains 25-D (isolated in 1984) and 90-12 (isolated in 199...
1 23 24 25 26 27 34